Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation

Transplantation

Volumn 92, Issue 12, 2011, Pages 1348-1357

  Ciancio, Gaetano ^a   Gaynor, Jeffrey J ^a   Sageshima, Junichiro ^a   Guerra, Giselle ^a   Zarak, Alberto ^a   Roth, David ^a   Brown, Randolph ^a   Kupin, Warren ^a   Chen, Linda ^a   Hanson, Lois ^a   Tueros, Lissett ^a   Ruiz, Phillip ^a   Livingstone, Alan S ^a   Burke, George W ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Alemtuzumab; Antithymocyte globulin; Biopsy proven acute rejection; Daclizumab; Enteric coated mycophenolate sodium; Graft survival; Renal transplantation; Steroid avoidance; Tacrolimus

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID; TACROLIMUS; THYMOCYTE ANTIBODY; CANCER ANTIBODY; CORTICOSTEROID; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MONOCLONAL ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCYTE DEPLETION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VIRUS HEPATITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; GRAFT REJECTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTILYMPHOCYTE SERUM; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84858415496     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182384b21     Document Type: Article

References (50)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
2. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
3. Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595.
4. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584.
5. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.
6. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. Transplantation 2004; 77: 244.
7. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252.
8. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate versus cyclosporine/ sirolimus in renal transplantation: Three-year analysis. Transplantation 2006; 81: 845.
9. Brennan DC, Daller JA, Lake KD, et al; for the Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006;355: 1967.
10. Kandus A, Arnol M, Omahen K, et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: A prospective, randomized study. Transplantation 2010; 89: 1022.
11. Ortiz J, Palma-Vargas J, Wright F, et al. Campath induction for kidney transplantation: Report of 297 cases. Transplantation 2008; 85: 1550.
12. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction-Long-term Results: Am J Transplant 2005; 5: 2539.
13. Ciancio G, BurkeGW,Gaynor JJ, et al.Arandomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457.
14. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up. Clin Transplant 2008; 22: 200.
15. Ciancio G, Gaynor JJ, Roth D, et al. Randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in living donor renal transplantation. Transplant Proc 2010; 42: 3503.
16. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-A 5-year experience. Am J Transplant 2005; 5: 2473.
17. Vincenti F, Schena FP, Paraskevas S, et al; on behalf of the FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
18. Woodle ES, First MR, Pirsch J, et al; for the Astellas Corticosteroid Withdrawal Study Group. A prospective randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
19. Burke GW, Ciancio G, Figueiro J, et al. Can acute rejection be prevented in SPK transplantation? Transplant Proc 2002; 34: 1913.
20. Burke GW III, Ciancio G, Figueiro J, et al. Steroid-resistant acute rejection following SPK: Importance of maintaining therapeutic dosing in a triple-drug regimen. Transplant Proc 2002; 34: 1918.
21. Ruggenenti P, Codreanu I, Cravedi P, et al. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: A possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 546.
22. Favi E, Gargiulo A, Spagnoletti G, et al. Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: Six-month results of a prospective clinical study. Transplant Proc 2010; 42: 1114.
23. Ciancio G, Burke GW, Gaynor JJ, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: One year follow-up. Transplantation 2008; 86: 67.
24. Ciancio G, Gaynor JJ, Zarak A, et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: Four year analysis. Transplantation 2011; 91: 1198.
25. Sageshima J, Ciancio G, Gaynor JJ, et al. Addition of anti-CD25 to thymoglobulin for induction therapy: Delayed return of peripheral blood CD25 positive population. Clin Transplant 2011; 25: E132.
26. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplant. Transplantation 1998; 66: 29.
27. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798.
28. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507.
29. Zand MS. B-cell activity of polyclonal antithymocyte globulins. Transplantation 2006; 82: 1387.
30. Ciancio G, Burke GW. Minireview: Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15.
31. Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant 2010; 10: 2132.
32. Kreijveld E, Koenen HJPM, Klasen IS, et al. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007; 7: 249.
33. Matas AJ, Gillingham KJ, Payne WD, et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857.
34. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil en de novo renal transplant patients. Am J Transplant 2003; 4: 231.
35. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of 1-year study. Am J Transplant 2003; 4: 237.
36. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59: 655.
37. Humar A, Hassoun A, Kandaswamy R, et al. Immunologic factors: The major risk for decreased long-term renal allograft survival. Transplantation 1999; 68: 1842.
38. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
39. Tierce JC, Porterfield-Baxa J, Petrilla AA, et al. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005; 19: 779.
40. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200.
41. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
42. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89: 1.
43. Mancinelli LM, Frassetto L, Floren LC, et al. The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups. Clin Pharmacol Ther 2001; 69: 24.
44. Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosuppressants: Aperspective on ethnic differences. Int J Clin Pharmacol Ther 2004; 42: 701.
45. Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88: 810.
46. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
47. Ciancio G, Gaynor JJ, Sageshima J, et al. Favorable outcomes with machine perfusion and longer pump times in kidney transplantation:A single-center, observational study. Transplantation 2010; 90: 882.
48. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
49. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: Updates and future directions. Am J Transplant 2008; 8: 753.
50. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames, IA: The Iowa State University Press 1967.